Publisher
Springer Berlin Heidelberg
Reference6 articles.
1. Haustein K.-O., Hüller G. (1985): Zur Bioverfügbarkeit von Etilefrin aus Thomasin® und Thomasin retard®-Tabletten. Pharmazie 40: 776–778.
2. Hengstmann J. H., Hengstmann R., Schwonzen S., Dengler H. J. (1983): Dihydroer-gotamine increases the bioavailability of orally administered etilefrin in man. Eur. J. Clin. Pharmacol. 22: 463–467.
3. Inoue H., Inoue K., Arndt J. O. (1980): Interaction of dihydroergotamine and etile-frine-hydrochloride at capacitance vessels of the calf in man. Z. Kardiol. 69: 280–286.
4. Maurer G., Frick W. (1984): Elucidation of the structure and receptor binding studies of the major primary metabolite of dihydroergotamine in man. Eur. J. Clin. Pharmacol. 26: 463–470.
5. Thulesius O. (1975): Die Therapie der arteriellen Hypotonie. Med. Welt 26: 588–591.